CD80 and neoplasm: Although conflicting evidence exists for whether cis PD-L1:CD80 heterodimers or CD80 alone is more efficient at inducing T cell responses (71, 74), our data suggest that in tumors with a high DC signature, PD-L1 therapies may be more beneficial as it may prolong neoantigen-bearing DC localization in the tumor.